CLINICAL TRIAL

RET-IRD-04

Retinal RED
Neuroophthalmology RED
Pediatric RED

Interventional

Phase 3

Efficacy and safety of QLT091001 in subjects with Inherited Retinal Disease (IRD) caused by gene mutations.

Rare Eye Disease concerned by the trial :
Leber Congenital Amaurosis due to RPE65 Mutations

Status of the trial : Not yet recruiting

Orphan drug recognition : Yes

Inclusion criteria : Genotype-confirmed Leber congenital amaurosis attributable

Exclusion criteria : Prior gene therapy

Inclusion opening date : 12/12/2017

Inclusion closing date (previsionnal) : 12/12/2018

Children ☑

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Rigshospitalet
Blegdamsvej 9
2100 København Ø
Danemark

Contact details

Principal investigator name :
Michael Larsen

Other investigators :
Line Kessel

Rigshospitalet - Glostrup
Valdemar Hansens Vej 1-23
2600 Glostrup
Danemark



Funder type : Drug company - Industry